Hostname: page-component-78c5997874-lj6df Total loading time: 0 Render date: 2024-10-31T23:14:44.514Z Has data issue: false hasContentIssue false

Functioning in patients with recently diagnosed vs. chronic schizophrenia treated with paliperidone ER

Published online by Cambridge University Press:  16 April 2020

C. Tessier
Affiliation:
Janssen EMEA, Issy Les Moulineaux, France
M. Franco
Affiliation:
Psychiatry Department Zamora Hospital, Zamora, Spain
B. Millet
Affiliation:
Service de Psychiatrie Adulte, Centre Hospitalier Guillaume Regnier-SPAO, Rennes, France
E. Sachetti
Affiliation:
Clinica Psichiatrica Spidali Civili di Breschia, Breschia, Italy
J. Turczynsky
Affiliation:
Department of Developmental-Psychotic and Geriatric Psychiatry, Medical University of Gdansk, Gdansk, Poland
R. Vauth
Affiliation:
Psychiatric Outpatients Department, University Hospital of Basel, Basel, Switzerland
D. Hoeben
Affiliation:
Janssen EMEA, Beerse, Belgium
M. Lahaye
Affiliation:
Janssen EMEA, Tilburg, The Netherlands
A. Schreiner
Affiliation:
Janssen EMEA, Neuss, Germany

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Objective

To explore functioning in adult patients with recently diagnosed (< 5 years) and more chronic (> 5 years) schizophrenia treated with flexible doses of paliperidone ER.

Methods

International prospective open-label 6-month study. Endpoints were the Positive and Negative Syndrome Scale (PANSS), patient functioning (Personal and Social Performance Scale; PSP) and treatment-emergent adverse events (TEAEs).

Results

Of 713 recently diagnosed patients, most were male (60.9%), mean age was 33.6 ± 11.2 years and mean time since diagnosis was 2.3 ± 1.7 years. Chronic patients (n = 1003) were predominantly male (59.2%) with a mean age of 43.8 ± 11.4 and mean time since diagnosis of 15.6 ± 9.2 years. Mean mode doses of paliperidone ER were similar between recently diagnosed and chronic patients (7.0 ± 2.9 mg/day and 7.2 ± 2.9 mg/day). At endpoint PANSS total scores were improved by 13.7 and 12.9 points, respectively, in recently diagnosed and chronic patients. The rate of patients with mild or less functional impairment increased from 17.7% to 39.8% in recently diagnosed and from 14.4% to 32.9% in chronic patients. Major functional improvements were observed for socially useful activities and personal and social relationships. TEAEs reported in >5% of recently diagnosed or chronic patients were insomnia (10.7% and 8.1%), anxiety (8.6% and 6.0%) and somnolence (5.8% and 3.4%), respectively.

Conclusion

These data suggest that both recently diagnosed and chronic patients previously unsuccessfully treated with other oral antipsychotics may benefit from paliperidone ER, with a tendency for recently diagnosed patients showing some higher treatment response in psychotic symptoms and patient functioning, particularly in socially useful activities and personal and social relationships.

Type
P03-116
Copyright
Copyright © European Psychiatric Association 2011
Submit a response

Comments

No Comments have been published for this article.